Strategic medical plans, their objectives and the initiatives that deliver them. Every initiative must trace to an approved objective.
Active plans
Objectives on track / at risk / off track
| Plan | Product | Scope | Lifecycle stage | Period | Status | Version | Owner | Budget planned vs actual | Review date |
|---|---|---|---|---|---|---|---|---|---|
Vantrexa Global Medical Plan FY2026 MP-2026-VTX-G | Vantrexa | Global | Launch | FY2026 | Active | v3 | PRDr. Priya Raman | 71% $5.9M of $8.4M | 01 Oct 2026 |
Vantrexa Japan Country Plan FY2026 MP-2026-VTX-JP | Vantrexa | Japan | Launch | FY2026 | Active | v2 | KWDr. Kenji Watanabe | 58% $640k of $1.1M | 15 Nov 2026 |
| Objective | Product | Owner | Status | Progress | Confidence | Initiatives | Plan |
|---|---|---|---|---|---|---|---|
Establish vantrelimab as the preferred chemotherapy-free first-line option in PD-L1 ≥ 50% NSCLC amo… SO-VTX-01 | Vantrexa | PRDr. Priya Raman | On track | 68% | High | 2 | Vantrexa Global Medical Plan FY2026 |
Close the post-progression sequencing evidence gap through a real-world cohort and expert consensus. SO-VTX-02 | Vantrexa | NPDr. Nikolai Petrov | At risk | 41% | Medium | 2 | Vantrexa Global Medical Plan FY2026 |
Ensure PD-L1 testing readiness so that ≥ 80% of eligible patients in launch markets have a result w… SO-VTX-03 | Vantrexa | SLDr. Sophie Laurent | On track | 74% | Medium | 1 | Vantrexa Global Medical Plan FY2026 |
Deliver a complete, approved scientific communication platform and medical-information response lib… SO-VTX-04 | Vantrexa | DCDavid Chen | On track | 88% | High | 1 | Vantrexa Global Medical Plan FY2026 |
Achieve JSMO scientific presence and Tier 1 KOL coverage in Japan ahead of PMDA approval. SO-VTX-JP-01 | Vantrexa | KWDr. Kenji Watanabe | At risk | 52% | Medium | 1 | Vantrexa Japan Country Plan FY2026 |
| Initiative | Type | Product | Objective | Owner | Dates | Status | Priority | Progress | Budget vs spend |
|---|---|---|---|---|---|---|---|---|---|
| Field medical campaign | Vantrexa | SO-VTX-01 | JWJames Whitfield | 15 Jan 2026 – 15 Dec 2026 | In progress | Critical | 66% | $418k / $620k | |
| RWE project | Vantrexa | SO-VTX-02 | NPDr. Nikolai Petrov | 01 Mar 2026 – 30 Jun 2027 | At risk | High | 30% | $310k / $1.4M | |
| Publication project | Vantrexa | SO-VTX-02 | DCDavid Chen | 01 Apr 2026 – 31 Dec 2026 | In progress | High | 55% | $52k / $95k | |
| Medical education program | Vantrexa | SO-VTX-03 | SLDr. Sophie Laurent | 01 Feb 2026 – 30 Nov 2026 | In progress | High | 78% | $296k / $380k | |
| Launch-readiness workstream | Vantrexa | SO-VTX-04 | DCDavid Chen | 10 Jan 2026 – 30 Sept 2026 | In progress | Critical | 90% | $221k / $240k | |
ESMO 2026 congress plan INI-0106 | Congress activity | Vantrexa | SO-VTX-01 | DCDavid Chen | 01 May 2026 – 31 Oct 2026 | In progress | High | 60% | $198k / $510k |
| Field medical campaign | Vantrexa | SO-VTX-JP-01 | KWDr. Kenji Watanabe | 01 Mar 2026 – 20 Dec 2026 | At risk | High | 48% | $172k / $310k |